Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dasatinib + RO7283420 + Tocilizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 29 BTK inhibitor 33 CSF1R Inhibitor 28 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 55 PDGFR Inhibitor (Pan) 28 SRC Inhibitor 31 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|RO7283420||RO-7283420|RO 7283420|RG6007|RG-6007|RG 6007|HLA-A2-WT1 x CD3 RG6007||CD3 Antibody 75||RO7283420 is a T-cell receptor-like T-cell engaging bispecific antibody (T-BsAb) that targets a 9-amino acid peptide derived from Wilms tumor 1 (WT1) and CD3 expressed on T-lymphocytes, which potentially leads to a cytotoxic T-lymphocyte response against tumor cells expressing WT1 (NCI Drug Dictionary).|
|Tocilizumab||Actemra||Atlizumab||Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04580121||Phase I||Dasatinib + RO7283420 + Tocilizumab||A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.||Recruiting||USA | ITA | FRA | ESP | DEU | CAN||4|